Acadian Asset Management
STLN

Acadian Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Acadian Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-38,639
Closed -$60K – 1903
2024
Q1 		$60K Hold
38,639
– – ﹤0.01% 1362
2023
Q4 		$78K Buy
+38,639
New +$67K ﹤0.01% 1397

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.62B AUM 18.42% 1-Year Est. Return
BFM
Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's STLN Position: Q2 2024 in Review

Acadian Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2024, closing a stake of 38,639 shares — an estimated $60K sold.

Acadian Asset Management first reported a position in STLN in Q4 2023 and held it in 2 quarters. The position peaked at $78K in Q4 2023. 39 funds tracked by Wall St. Rank hold STLN as of Q2 2024.

  • Acadian Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 38,639 Starling Oncology Institute, Inc. Common Stock shares in Q2 2024, an estimated $60K.
  • Acadian Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Acadian Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $78K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.